Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 2/20 | 0.56 |
| ▸ | FLT4 | P35916 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17286572 | 0.82 | ALDH1A1 (0.54) | FLT1FLT4KDRATMEGFR | |
| SCHEMBL15271107 | 0.82 | EGFR (0.59) | FLT1FLT4KDRATMEGFR | |
| SCHEMBL2543543 | 0.81 | PKM (0.56) | PKMDHFRTSHRSMN1; SMN2TDP1 | |
| SCHEMBL9888787 | 0.81 | FBP1 (0.63) | FLT1FLT4KDR | |
| SCHEMBL3373698 | 0.80 | FBP1 (0.55) | ATM | |
| SCHEMBL13649414 | 0.79 | PKM (0.54) | PKMDHFRTSHRSMN1; SMN2TDP1 | |
| SCHEMBL6297904 | 0.79 | TSHR (0.64) | PKMDHFRTSHRSMN1; SMN2TDP1 | |
| SCHEMBL11930742 | 0.79 | FBP1 (0.63) | FLT1FLT4KDRPKM | |
| SCHEMBL1511755 | 0.79 | FLT1 (0.49) | FLT1FLT4KDRATMEGFR | |
| SCHEMBL31629397 | 0.79 | FLT1 (0.49) | FLT1FLT4KDRATMEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117603101-A | Lewis acid-promoted non-hydrolytic deacylation method for N-acyl secondary sulfonamide | 荆楚理工学院 | 2024-02-27 | — | — | CN | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| CN-103214450-B | 1-(benzo [D] [1,3] dioxole-5-base)-N-(phenyl) cyclopropane-carboxamides derivatives as ATP-binding cassette transport protein regulator | 弗特克斯药品有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150065497-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-03-05 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-8846753-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2016065-B1 | 1-(BENZO[D][1,3]DIOXOL-5-YL)-N-(PHENYL)CYCLOPROPANE-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8039491-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100249113-A1 | MODULATORS OF ATP BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100105739-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| US-7691902-B2 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-7671221-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-02 | — | — | US | disclosed |
| CN-101395147-A | 1- (benzo [ D ] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane-carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis | VERTEX PHARMA (US) | 2009-03-25 | — | — | CN | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | FLT1 2826/4885FLT4 3537/4885KDR 3568/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | FLT1 4005/4885FLT4 4286/4885KDR 4660/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FLT1 4005/4885FLT4 4286/4885KDR 4660/4885 |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | FLT1 3220/4885FLT4 3051/4885KDR 2651/4885 |
| US-20100105739-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | FLT1 3220/4885FLT4 3051/4885KDR 2651/4885 |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FLT1 4005/4885FLT4 4286/4885KDR 4660/4885 |
| US-20150065497-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | FLT1 3220/4885FLT4 3051/4885KDR 2651/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | FLT1 3016/4885FLT4 3078/4885KDR 3663/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FLT1 4005/4885FLT4 4286/4885KDR 4660/4885 |
| US-20100249113-A1 | MODULATORS OF ATP BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | FLT1 3181/4885FLT4 2985/4885KDR 2710/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | FLT1 4005/4885FLT4 4286/4885KDR 4660/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | FLT1 1627/4885FLT4 1272/4885KDR 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.